Wu Songjiang, Lei Li, Hu Yibo, Jiang Ling, Fu Chuhan, Zhang Yushan, Zhu Lu, Huang Jinhua, Chen Jing, Zeng Qinghai
Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Fundam Res. 2023 Mar 21;5(3):1313-1322. doi: 10.1016/j.fmre.2023.02.021. eCollection 2025 May.
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease seriously affecting the quality of life of patients. Reliable and accurate evaluation methods are necessary for early diagnosis and effective AD treatment. Thus, this study used machine learning (ML) to explore a novel diagnostic and therapeutic effect evaluation model for AD. Firstly, candidate model genes were screened from an integrated data set of four AD-related microarray datasets: GSE133477, GSE32924, GSE58558, and GSE107361, using Robust Rank Aggregation (RRA), and protein-protein interaction network (PPI). Next, three recognized models (REC) and three AD-associated gene models (AAG) established with LASSO, Logistic linear regression (LR), and random forest (RF) were developed and tested separately using GSE130588 and GSE99802 datasets. The results revealed that REC model of LASSO (model genes including and ), REC model of LR(including ) and AAG model of LR (including ) accurately classified AD lesions and non-lesions based on the good AUCs (LASSO (REC):0.8761, and LR (REC and AAG):0.8302 in GSE130588; LASSO (REC): 0.7761, and LR (REC and AAG):0.8783 in GSE99802). In Dupilumab, Crisaborole, and fezakinumab-treated samples, the LASSO (REC) and LR(AAG) models were positively correlated with SCORD (Pearson correlation coefficients of 0.55 and 0.69, respectively) and negatively correlated with the treatment length. In addition, the two models also accurately predicted the infiltration of immune cells in the skin lesions and non-lesions. Therefore, the ML-based predictive model provides a new approach to predicting AD diagnosis and the therapeutic effect of AD treatment options.
特应性皮炎(AD)是最常见的慢性炎症性皮肤病,严重影响患者的生活质量。可靠且准确的评估方法对于AD的早期诊断和有效治疗至关重要。因此,本研究使用机器学习(ML)来探索一种新的AD诊断和治疗效果评估模型。首先,使用稳健秩聚合(RRA)和蛋白质-蛋白质相互作用网络(PPI),从四个与AD相关的微阵列数据集(GSE133477、GSE32924、GSE58558和GSE107361)的整合数据集中筛选候选模型基因。接下来,分别使用GSE130588和GSE99802数据集开发并测试了用LASSO、逻辑线性回归(LR)和随机森林(RF)建立的三个公认模型(REC)和三个AD相关基因模型(AAG)。结果显示,基于良好的曲线下面积(AUC),LASSO的REC模型(模型基因包括 和 )、LR的REC模型(包括 )和LR的AAG模型(包括 )能够准确区分AD皮损和非皮损(在GSE130588中,LASSO(REC):0.8761,LR(REC和AAG):0.8302;在GSE99802中,LASSO(REC):0.7761,LR(REC和AAG):0.8783)。在度普利尤单抗、克立硼罗和非扎金umab治疗的样本中,LASSO(REC)和LR(AAG)模型与SCORD呈正相关(Pearson相关系数分别为0.55和0.69),与治疗时长呈负相关。此外,这两个模型还准确预测了皮损和非皮损中免疫细胞的浸润情况。因此,基于ML的预测模型为预测AD诊断和AD治疗方案的治疗效果提供了一种新方法。